At a Glance
Chemotherapy for prostate cancer — most commonly docetaxel or cabazitaxel — is used when cancer has spread beyond the prostate or has stopped responding to hormone therapy. It is not typically used for early, localised prostate cancer, where treatments such as focal therapy, surgery, radiotherapy, or active surveillance are more appropriate. For men with metastatic disease, chemotherapy may help control cancer, relieve symptoms, and in some cases extend survival — often given alongside hormone therapy under NICE guideline NG131.
Key takeaways
- For advanced disease only: chemotherapy is used for metastatic or hormone-resistant prostate cancer, not early localized disease.
- Two main drugs: docetaxel (used first) and cabazitaxel (used after docetaxel if needed), are the standard chemotherapy agents for prostate cancer.
- Given in cycles: typically once every three weeks through a drip into a vein, usually for six cycles in metastatic disease.
- Side effects are manageable but real: fatigue, infection risk, nausea, hair loss, and nerve symptoms are common. Your team will monitor you closely throughout.
- Focal therapy is a different pathway: For men with localized prostate cancer, focal therapy (HIFU, NanoKnife) treats the cancer within the prostate and is not a chemotherapy treatment.
When is chemotherapy used for prostate cancer?
Chemotherapy is not usually used for prostate cancer that is only inside the prostate. It is more often used when prostate cancer has spread to other parts of the body. This may include bones, lymph nodes, lungs or liver.
Your oncologist may discuss chemotherapy if:
- The cancer is newly diagnosed and metastatic
- The cancer is causing symptoms
- The cancer is growing despite hormone therapy
- The disease is aggressive
- You are fit enough for chemotherapy
- Other systemic treatments are not suitable or have stopped working
Chemotherapy may be part of the first treatment plan for some men with metastatic prostate cancer. It may also be used later in the disease pathway.
Advanced or metastatic prostate cancer
Metastatic prostate cancer means cancer cells have spread beyond the prostate.
Treatment aims to control the cancer, reduce symptoms and help some men live longer. Chemotherapy may be one part of this plan.
For newly diagnosed metastatic prostate cancer, docetaxel may be offered with androgen deprivation therapy. This is a type of hormone therapy that lowers testosterone.
Some men may also be offered newer hormone tablets. These include medicines such as abiraterone, enzalutamide, apalutamide or darolutamide. These are not chemotherapy drugs. They are systemic cancer treatments that target hormone signalling.
Your oncologist will recommend a plan based on your cancer, symptoms, scans, blood tests, fitness and other medical conditions.
Hormone-resistant prostate cancer
Most prostate cancers depend on testosterone to grow. Hormone therapy lowers or blocks testosterone.
Over time, some prostate cancers keep growing despite low testosterone levels. This is called castration-resistant prostate cancer. If the cancer has also spread, it is called metastatic castration-resistant prostate cancer.
Chemotherapy may be used at this stage. Docetaxel is often used first if it has not already been given. Cabazitaxel may be considered after docetaxel, especially if the cancer has also grown after newer hormone tablets.
The exact sequence depends on previous treatment and your general health.
High-risk or aggressive disease
Some prostate cancers behave more aggressively. Chemotherapy may be discussed earlier if the cancer has already spread and you are fit enough for treatment.
Rare types of prostate cancer, such as small-cell or neuroendocrine prostate cancer, may also need different chemotherapy drugs. These cancers behave differently from prostate ‘adenocarcinoma’ (the most common type). Your team may recommend extra tests if the cancer pattern is unusual.
Common chemotherapy drugs for prostate cancer
The two main chemotherapy drugs used for typical advanced prostate cancer are docetaxel and cabazitaxel. They belong to a group of medicines called taxanes. They work by interfering with the way cancer cells divide and grow.
Docetaxel
Docetaxel is usually the first chemotherapy drug used for prostate cancer.
It may be used:
- with hormone therapy for newly diagnosed metastatic prostate cancer
- later, when metastatic prostate cancer becomes resistant to hormone therapy
Docetaxel may help slow cancer growth and improve survival for some men. It can also help control symptoms, including pain from bone metastases.
It is usually given once every three weeks through a drip into a vein. Many men also take steroid tablets, such as prednisolone, depending on the treatment plan.
Cabazitaxel
Cabazitaxel is usually used after docetaxel.
It may be considered if the cancer grows after docetaxel and other treatments. It can still work in some cancers that have become resistant to docetaxel.
Cabazitaxel is also given through a drip into a vein. It is usually given once every three weeks. It is commonly given with steroid tablets.
Cabazitaxel can cause low white blood cell counts. Some men need injections to boost white blood cells and reduce infection risk.
Other therapy drugs
Many modern prostate cancer treatments are not chemotherapy.
These include newer hormone tablets and targeted treatments. Examples include abiraterone, enzalutamide, apalutamide, darolutamide, PARP inhibitors and radioligand therapy for selected men.
These treatments work in different ways. Some are only suitable if genetic testing shows a specific cancer change.
How chemotherapy is given
Chemotherapy is usually given in a hospital cancer day unit.
A nurse gives the drug through a drip into a vein. This may be through a small tube in your hand or arm. Some men need a longer line, such as a PICC line or central line.
Before each cycle, you will usually have blood tests. These check whether your blood counts, liver function and kidney function are safe for treatment.
You may also receive medicines to reduce the risk of sickness or allergic reaction.
Treatment cycles and planning
Chemotherapy is given in cycles.
A cycle means one treatment followed by a rest period. This gives your body time to recover before the next dose.
For prostate cancer, docetaxel is often given every three weeks. NICE recommends six three-weekly cycles for newly diagnosed metastatic prostate cancer in men without significant comorbidities. In later hormone-resistant disease, treatment length may differ.
Your oncologist may stop, delay or reduce treatment if side effects are significant.
Combined with other treatments
Chemotherapy is often combined with hormone therapy.
This is because hormone therapy and chemotherapy work in different ways. For some men with metastatic prostate cancer, using treatments together can improve cancer control compared with hormone therapy alone.
Some men may also receive radiotherapy to the prostate or to painful bone areas. Radiotherapy for bone pain is usually given to relieve symptoms.
For men with cancer still contained within the prostate, local treatments are usually considered instead of chemotherapy. These may include surgery, radiotherapy, brachytherapy, active surveillance or focal therapy in selected cases.
Get Expert Advice & The Latest Research
Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.
Side effects of chemotherapy for prostate cancer
Chemotherapy can cause side effects because it also affects some healthy fast-growing cells.
Not every man gets every side effect. The pattern depends on the drug, dose, number of cycles and your general health. Your team will explain what to look for and who to contact.
Common short-term side effects
Common short-term side effects may include: tiredness, increased risk of infection, hair loss, feeling sick, loss of appetite, taste changes, diarrhoea or constipation, sore mouth, nail changes, bruising or bleeding more easily, breathlessness from anaemia. The infection risk is important. Chemotherapy can lower white blood cells, which help fight infection.
Contact your hospital advice line urgently if you feel unwell, have a temperature, feel shivery, develop a cough, or have burning when passing urine. Your team will tell you the exact temperature range that needs urgent action.
Longer-term or cumulative effects
Some side effects build up over time. These may include: ongoing fatigue, numbness or tingling in the hands or feet, reduced physical fitness, nail changes, changes in memory or concentration, lower blood counts.
Numbness or tingling is called peripheral neuropathy. It may improve after treatment, but it can sometimes last longer.
Tell your team early if you notice nerve symptoms. Your dose may need adjustment, for example.
Balancing benefits and risks
Chemotherapy can help some men live longer and control symptoms. It can also cause side effects that affect daily life. The decision depends on what treatment is likely to achieve for you. Your oncologist will consider things like:
- where the cancer has spread
- how quickly it is growing
- your PSA pattern
- your scan results
- symptoms such as pain
- previous treatments
- kidney, liver and bone marrow function
- fitness and frailty
- other medical conditions
- your personal priorities
Some men value a treatment that may extend life, even with side effects. Others place more weight on day-to-day quality of life.
Chemotherapy vs other prostate cancer treatments
Prostate cancer treatment is not one-size-fits-all. Chemotherapy is one option among many. It is mainly used for cancer that has spread or become resistant to hormone therapy.
Local vs systemic treatment
Local treatments target the prostate itself.
These include:
- surgery
- external beam radiotherapy
- brachytherapy
- focal therapy
Systemic treatments travel through the body. They are used when cancer has spread, or when there is a high risk that cancer cells may be outside the prostate.
Systemic treatments include:
- hormone therapy
- chemotherapy
- newer hormone tablets
- targeted therapy
- radioligand therapy in selected men
Chemotherapy is a systemic treatment.
Where focal therapy fits
Focal therapy is not a chemotherapy treatment.
It is a local treatment for selected men with localised prostate cancer. It treats the known cancer area rather than the whole prostate. Focal therapy aims to reduce damage to surrounding tissue and aims to preserve urinary continence and erectile function. It is not suitable for all men.
Suitability depends on MRI findings, biopsy results, cancer grade, cancer volume and cancer position. If prostate cancer has already spread to other parts of the body, focal therapy is usually not the main treatment. Systemic treatment is usually needed.
Deciding whether chemotherapy is right for you
Starting chemotherapy is a significant decision.
It is worth taking time to understand the likely benefits, side effects and alternatives.
You may wish to ask your oncologist or urologist:
- Why are you recommending chemotherapy now?
- What are the expected benefits for my cancer?
- What side effects are most likely?
- How many cycles are planned?
- What happens if I do not tolerate treatment?
- What happens if the cancer grows despite chemotherapy?
- Are there non-chemotherapy options?
- Are clinical trials suitable for me?
- Who do I contact if I feel unwell?
You can find more ideas in our guide to questions for your urologist.
FAQs
References
National Institute for Health and Care Excellence. (2025). Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA1109). Available at: https://www.nice.org.uk/guidance/ta1109
National Institute for Health and Care Excellence. (2025). Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA1110). Available at: https://www.nice.org.uk/guidance/ta1110
European Association of Urology. (2026). EAU Guidelines on Prostate Cancer. Available at: https://uroweb.org/guidelines/prostate-cancer
Cancer Research UK. (n.d.). Chemotherapy for metastatic prostate cancer. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment/chemotherapy
Prostate Cancer UK. (n.d.). Chemotherapy. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/chemotherapy
Prostate Cancer UK. (n.d.). Side effects of chemotherapy. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/side-effects-of-chemotherapy
